This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.


This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Speaker - Jörn Schattenberg
University Medical Center, Mainz, Germany

Jörn M. Schattenberg is a Professor of Medicine and Director of the Metabolic Liver Research Program at the University Medical Center Mainz, Germany. He received his medical degree in 2002 after studying at the University of Mainz (Germany) and at the Tulane University in New Orleans (US). He completed his post-doctoral training at the Albert-Einstein College of Medicine, New York, where he focused on delineating signalling pathways involved in the pathophysiology of acute and chronic liver injury with a special focus on metabolic liver disease and non-alcoholic steatohepatitis (NASH).


He is board-certified in Internal Medicine and Gastroenterology & Hepatology and Infectious Disease. He built up the Metabolic Liver Research Program that focuses on translational sciences and clinical trials. Additionally, he heads a liver research laboratory focusing on clinical and experimental aspects of liver injury, the development of therapeutic intervention and novel biomarkers in liver disease.


Professor Schattenberg is member of the Scientific Committee of the United European Gastroenterology (UEG), member of the Policy and Public Health Committee of the European Association for the Study of the Liver (EASL) and a member of the Editorial Board of Hepatology and the Alimentary Pharmacology & Therapeutics.